目的 探讨舒肝益脾胶囊联合恩替卡韦分散片治疗乙型肝炎肝硬化的临床疗效。方法 选取2015年10月-2017年10月阳新县人民医院收治的100例乙型肝炎肝硬化患者为研究对象，将所有患者采用抽签方式分为对照组和治疗组，每组各50例。对照组患者口服恩替卡韦分散片，0.5 mg/次，1次/d。治疗组患者在对照组基础上口服舒肝益脾胶囊，5粒/次，3次/d。两组患者均接受治疗6个月。观察两组的临床疗效，比较两组的肝功能指标、肝纤维化指标。结果 治疗后，对照组和治疗组的总有效率分别为82.00%、96.00%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者丙氨酸氨基转移酶（ALT）、天门冬氨酸氨基转氨酶（AST）和总胆红素（TBIL）水平均显著降低，白蛋白（ALB）水平显著升高，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组患者肝功能指标水平明显优于对照组，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者透明质酸（HA）、Ⅲ型前胶原（PCⅢ）、层黏连蛋白（LN）、Ⅳ型胶原（Ⅳ-C）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；并且治疗组肝纤维化指标水平明显低于对照组，两组比较差异有统计学意义（P<0.05）。结论 舒肝益脾胶囊联合恩替卡韦分散片治疗乙型肝炎肝硬化具有较好的临床疗效，能有效改善患者肝功能和肝纤维化，安全性较好，具有一定的临床推广应用价值。

Objective To investigate the efficacy of Shugan Yipi Capsules combined with Entecavir Dispersible Tablets in treatment of hepatitis B cirrhosis. Methods Patients (100 cases) with hepatitis B cirrhosis in Yangxin People's Hospital from October 2015 to October 2017 were randomly divided into control and treatment groups, and each group had 50 cases. Patients in the control group were po administered with Entecavir Dispersible Tablets, 0.5 mg/time, once daily. Patients in the treatment group were po administered with Shugan Yipi Capsules on the basis of the control group, 5 grains/time, three times daily. Patients in two groups were treated for 6 months. After treatment, the clinical efficacies were evaluated, and liver function indexes and liver fibrosis indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.00% and 96.00%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of ALT, AST, and TBIL in two groups were significantly decreased, but the levels of ALB in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the liver function indexes levels in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of HA, PCⅢ, LN and Ⅳ-C in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the liver fibrosis indexes levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Shugan Yipi Capsules combined with Entecavir Dispersible Tablets has clinical curative effect in treatment of hepatitis B cirrhosis, can improve liver function and liver fibrosis in patients, with good safety, which has a certain clinical application value.

R978.7